Login Register Cart 0
Generic placeholder image

Current Drug Research Reviews

Editor-in-Chief

ISSN (Print): 2589-9775
ISSN (Online): 2589-9783

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Is Cannabis Harmless? Focus on Brain Function

Author(s): John C. Ashton*

Volume 11, Issue 1, 2019

Page: [33 - 39] Pages: 7

DOI: 10.2174/2589977511666180809165622

Abstract

Background: The degree to which cannabis use causes long term harm to mental functioning is contentious.

Objective: To determine the evidence for residual and long term effects of cannabis use on mental functions.

Method: Comprehensively review human studies addressing detrimental effects on human mental and life functioning.

Results: Heavy use causes immediate effects on perception, mood and sedation, but also deficits in cognitive ability. But cessation following heavy use has withdrawal effects and is associated with residual effects on cognition that may last for several weeks. Heavy use also raises the risk of impoverishment of life outcomes and a decline in socioeconomic status as well as the risk of mental health problems. Young age at the start of heavy cannabis use causes a risk of lifelong detrimental effects, and as a worst case together with genetic vulnerability exacerbate a predisposition to schizophrenia.

Conclusion: Heavy regular use of cannabis that begins in adolescence heightens the risk of longterm impairment of life and mental functioning.

Keywords: Cannabis, harm, life outcomes, model, adolescence, cessation.

« Previous Next »
Graphical Abstract

[1]
Maroon J, Bost J. Review of the neurological benefits of phytocannabinoids. Surg Neurol Int 2018; 9: 91.
[2]
Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009; 374(9698): 1383-91.
[3]
Busardò FP, Pellegrini M, Klein J, di Luca NM. Neurocognitive correlates in driving under the influence of cannabis. CNS Neurol Disord Drug Targets 2017; 16(5): 534-40.
[4]
Habboushe J, Rubin A, Liu H, Hoffman RS. The prevalence of cannabinoid hyperemesis syndrome among regular marijuana smokers in an urban public hospital. Basic Clin Pharmacol Toxicol 2018; 122(6): 660-2.
[5]
Sorensen CJ, DeSanto K, Borgelt L, Phillips KT, Monte AA. Cannabinoid hyperemesis syndrome: Diagnosis, pathophysiology, and treatment—a systematic review. J Med Toxicol 2017; 13(1): 71-87.
[6]
Wolff V, Lauer V, Rouyer O, et al. Cannabis use, ischemic stroke, and multifocal intracranial vasoconstriction: A prospective study in 48 consecutive young patients. Stroke 2011; 42(6): 1778-80.
[7]
Sarne Y, Mechoulam R. Cannabinoids: Between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord 2005; 4(6): 677-84.
[8]
National Academies of Sciences E. Medicine The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press 2017.
[9]
Hall W. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? Addiction 2015; 110(1): 19-35.
[10]
Ashton JC, Milligan ED. Cannabinoids for the treatment of neuropathic pain: clinical evidence. Curr Opin Investig Drugs 2008; 9(1): 65-75.
[11]
Mannucci C, Navarra M, Calapai F, et al. Neurological aspects of medical use of cannabidiol. CNS Neurol Disord Drug Targets 2017; 16(5): 541-53.
[12]
Fried P, Watkinson B, James D, Gray R. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults. Can Med Assoc J 2002; 166(7): 887-91.
[13]
Crean RD, Crane NA, Mason BJ. An evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. J Addict Med 2011; 5(1): 1.
[14]
Fridberg DJ, Queller S, Ahn W-Y, et al. Cognitive mechanisms underlying risky decision-making in chronic cannabis users. J Math Psychol 2010; 54(1): 28-38.
[15]
Fried P, Watkinson B, Gray R. Neurocognitive consequences of marihuana-a comparison with pre-drug performance. Neurotoxicol Teratol 2005; 27(2): 231-9.
[16]
Pope HG, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58(10): 909-15.
[17]
Crean RD, Tapert SF, Minassian A, MacDonald K, Crane NA, Mason BJ. Effects of chronic, heavy cannabis use on executive functions. J Addict Med 2011; 5(1): 9.
[18]
Prashad S, Dedrick ES, Filbey FM. Cannabis users exhibit increased cortical activation during resting state. Neuroimage 2018.
[19]
Schoeler T, Bhattacharyya S. The effect of cannabis use on memory function: an update. Subst Abuse Rehabil 2013; 4: 11.
[20]
Cousijn J, Vingerhoets WA, Koenders L, et al. Relationship between working‐memory network function and substance use: A 3‐year longitudinal fMRI study in heavy cannabis users and controls. Addict Biol 2014; 19(2): 282-93.
[21]
Battisti RA, Roodenrys S, Johnstone SJ, Respondek C, Hermens DF, Solowij N. Chronic use of cannabis and poor neural efficiency in verbal memory ability. Psychopharmacology 2010; 209(4): 319-30.
[22]
Hanson KL, Thayer RE, Tapert SF. Adolescent marijuana users have elevated risk-taking on the balloon analog risk task. J Psychopharmacol 2014; 28(11): 1080-7.
[23]
Montgomery C, Seddon A, Fisk J, Murphy PN, Jansari A. Cannabis‐related deficits in real‐world memory. Human Psychopharmacol Clin Exp 2012; 27(2): 217-25.
[24]
Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF. Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence. J Int Neuropsychol Soc 2007; 13(5): 807-20.
[25]
Tait RJ, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8‐Year trajectory in a young adult cohort. Addiction 2011; 106(12): 2195-203.
[26]
Lyons MJ, Bar J, Panizzon M, et al. Neuropsychological consequences of regular marijuana use: A twin study. Psychol Med 2004; 34(7): 1239-50.
[27]
Thames AD, Arbid N, Sayegh P. Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav 2014; 39(5): 994-9.
[28]
Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: A meta-analysis. Exp Clin Psychopharmacol 2012; 20(5): 420.
[29]
Meier MH, Hill ML, Small PJ, Luthar SS. Associations of adolescent cannabis use with academic performance and mental health: a longitudinal study of upper middle class youth. Drug Alcohol Depend 2015; 156: 207-12.
[30]
Hanson KL, Winward JL, Schweinsburg AD, Medina KL, Brown SA, Tapert SF. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. Addict Behav 2010; 35(11): 970-6.
[31]
Rioux C, Castellanos-Ryan N, Parent S, Vitaro F, Tremblay RE, Séguin JR. Age of cannabis use onset and adult drug abuse symptoms: A prospective study of common risk factors and indirect effects. Can J Psychiatry 2018; 63(7): 457-64.
[32]
Boden JM, Fergusson DM, Horwood LJ. Illicit drug use and dependence in a New Zealand birth cohort. Aust N Z J Psychiatry 2006; 40(2): 156-63.
[33]
Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacol 1999; 141(4): 395-404.
[34]
Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. Am J Psychiatry 2004; 161(11): 1967-77.
[35]
Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug Alcohol Depend 2007; 86(1): 22-9.
[36]
Vandrey R, Budney A, Hughes J, Liguori A. A within-subject comparison of withdrawal symptoms during abstinence from cannabis, tobacco, and both substances. Drug Alcohol Depend 2008; 92(1): 48-54.
[37]
Zehra A, Burns J, Liu CK, et al. Cannabis addiction and the brain: A review. J Neuroimmune Pharmacol 2018; 1-15.
[38]
Newton-Howes G, McBride S. Cannabis in New Zealand: Smoking gun or medicalised smokescreen? N Z Med J 2016; 129(1433): 13-6.
[39]
Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot–a review of the association between cannabis and psychosis. Front Psychiatry 2014; 5: 54.
[40]
Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller AD, Bromet E. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 1997; 23(2): 195.
[41]
Andréasson S, Engström A, Allebeck P, Rydberg U. Cannabis and schizophrenia A longitudinal study of swedish conscripts. Lancet 1987; 330(8574): 1483-6.
[42]
Moore TH, Zammit S, Lingford-Hughes A, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007; 370(9584): 319-28.
[43]
Di Forti M, Morrison PD, Butt A, Murray RM. Cannabis use and psychiatric and cogitive disorders: the chicken or the egg? Curr Opin Psychiatry 2007; 20(3): 228-34.
[44]
Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994; 51(4): 273-9.
[45]
Bühler B, Hambrecht M, Löffler W, Heiden W, Häfner H. Precipitation and determination of the onset and course of schizophrenia by substance abuse-a retrospective and prospective study of 232 population-based first illness episodes. Schizophr Res 2002; 54(3): 243-51.
[46]
Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry 2016; 79(7): 549-56.
[47]
Henquet C, Rosa A, Delespaul P, et al. COMT Val158Met moderation of cannabis‐induced psychosis: A momentary assessment study of ‘switching on’ hallucinations in the flow of daily life. Acta Psychiatr Scand 2009; 119(2): 156-60.
[48]
Degenhardt L, Hall W, Lynskey M. Testing hypotheses about the relationship between cannabis use and psychosis. Drug Alcohol Depend 2003; 71(1): 37-48.
[49]
Horwood LJ, Fergusson DM, Coffey C, et al. Cannabis and depression: an integrative data analysis of four Australasian cohorts. Drug Alcohol Depend 2012; 126(3): 369-78.
[50]
Notzon DP, Pavlicova M, Glass A, et al. ADHD is highly prevalent in patients seeking treatment for cannabis use disorders. J Att Disorders 2016; p. 1087054716640109.
[51]
Fergusson DM, Horwood LJ, Ridder EM. Conduct and attentional problems in childhood and adolescence and later substance use, abuse and dependence: Results of a 25-year longitudinal study. Drug Alcohol Depend 2007; 88: S14-26.
[52]
Hollis C, Groom MJ, Das D, et al. Different psychological effects of cannabis use in adolescents at genetic high risk for schizophrenia and with Attention Deficit/Hyperactivity Disorder (ADHD). Schizophr Res 2008; 105(1): 216-23.
[53]
Fergusson DM, Boden JM. Cannabis use and adult ADHD symptoms. Drug Alcohol Depend 2008; 95(1): 90-6.
[54]
Fergusson DM, Boden JM. Cannabis use and later life outcomes. Addiction 2008; 103(6): 969-76.
[55]
Fergusson DM, Boden JM, Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: Findings from the Christchurch Health and Development Study. Soc Psychiatry Psychiatr Epidemiol 2015; 50(9): 1317-26.
[56]
Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci 2012; 109(40): E2657-64.
[57]
Pledger M, Martin C, Cumming J. New Zealand Health Survey 2012/13: Characteristics of medicinal cannabis users. N Z Med J 2016; 129(1433): 25-36.
[58]
Newton-Howes G, McBride S. Medicinal cannabis: Moving the debate forward. N Z Med J 2016; 129(1445): 103-9.
[59]
Reinarman C, Nunberg H, Lanthier F, Heddleston T. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs 2011; 43(2): 128-35.
[60]
Hazekamp A, Ware MA, Muller-Vahl KR, Abrams D, Grotenhermen F. The medicinal use of cannabis and cannabinoids-an international cross-sectional survey on administration forms. J Psychoactive Drugs 2013; 45(3): 199-210.
[61]
Pacula RL, Jacobson M, Maksabedian EJ. In the weeds: A baseline view of cannabis use among legalizing states and their neighbours. Addiction 2016; 111(6): 973-80.
[62]
Hasin DS, Saha TD, Kerridge BT, et al. Prevalence of marijuana use disorders in the United States between 2001-2002 and 2012-2013. JAMA Psychiatry 2015; 72(12): 1235-42.

Rights & Permissions Print Cite
Article Metrics
101
5
© 2024 Bentham Science Publishers | Privacy Policy